Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Slides:

Advertisements

Similar presentations

AF647-RIS is internalized by TAMs in vivo.

Advertisements

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Figure 2S (Supplementary Data)

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Fig. 5 Local gel scaffold for T cell memory response.

STING stimulation in T cells inhibits cell cycle progression.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

MP cells consist of rapidly proliferating CD5hi and relatively quiescent CD5lo cells, both of which require CD28 signaling for Ki67 expression. MP cells.

Anti-SEMA4D and anti–CTLA-4 treatment is synergistic and increases the frequency of tumor-specific TILs and secretion of proinflammatory cytokines, while.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

MK-8628 augments T lymphocyte apoptosis.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Protection from 4T1 tumor rechallenge in treated mice.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Figure 3. Enhancement of cytokine production by CD8+ T cells at TT

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

CD11bhighCD27high conventional NK cells are converted into MDSCs

Stereotactic radiotherapy increases Tregs in tumors.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

CD94/NKG2A expression and presence is higher on tumor-infiltrating immune cells. CD94/NKG2A expression and presence is higher on tumor-infiltrating immune.

CD25 expression predicts effector and memory differentiation.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

5FU-induced specific activation of CD8+ T cells.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

Uptake of TEX by DCs in vivo.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Increased apoptotic levels after combined treatment with vincristine (VCR) and imatinib. Increased apoptotic levels after combined treatment with vincristine.

Increased apoptotic levels after combined treatment with DXR and imatinib. Increased apoptotic levels after combined treatment with DXR and imatinib. A–D.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

CCR5 enhances both HDR and SSA DNA repair.

Comparative effect of anti-TIM3 against experimental tumors.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

A, VEGFR2 staining in the tumor rim and center.

Cross-presentation of ova to ova-specific CD8+ T cells in vivo by ova-loaded gp96 surface-expressing tumor cells. Cross-presentation of ova to ova-specific.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Mutation of the Smad3 linker phosphorylation sites in 4T1 cells reduces putative stem cell population and tumor initiating frequency of cells from the.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

Ex vivo profiling of PD-1 blockade using MDOTS

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

WEE1 inhibition followed by TRAIL treatment results in apoptotic cell death in MB231 cells. WEE1 inhibition followed by TRAIL treatment results in apoptotic.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

TRP1 transnuclear CD8 T cells are tumoricidal in vitro.

Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated.

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. A–D, CellTrace-labeled CD45.1+ CD8+ T cells were transferred into CD45.2+ CD8−/− mice. The mice were inoculated with MC38 and treatment started 5 days after MC38 inoculation. Mice were sacrificed on day 9, and CD8+ CD45.1+ T cells in DLNs and tumor sites were analyzed. A, A schematic diagram of the experimental schedule. B, Representative FACS patterns stained with CD45.1 and CellTrace among the gate of CD8+ CD45.1+ T cells are shown (left). The frequencies of fully proliferated cells (tumor-reactive CTLs) were compared between groups (right). C, DLNs were stained with annexin V and propidium iodide (PI). Representative FACS profiles of annexin V and PI staining after gating on CellTrace− CD45.1+ CD8+ T cells are shown (left and middle). Frequency of apoptotic cells (annexin V+ PI+) was compared between treated groups (right). D, CD8+ CD45.1+ T cells in TILs were intracellularly stained with Bcl2. Representative FACS profiles of Bcl2 staining are shown (left). Frequency and MFI of Bcl2+ T cells among CD8+ T cells are shown (right). E, MC38-bearing mice were treated with anti–PD-L1 and bezafibrate on the same schedule as shown in Supplementary Fig. S1A. DLN cells on day 13 were stained with anti-CD8, anti-CD62L, anti-CD44, and Ki67. The number of Ki67+ T cells in CD8+ T cells is shown (left). Representative FACS profiles of P1–P3 among CD8+ T cells stained with Ki67 in mice treated with anti–PD-L1 and bezafibrate (middle). The number of Ki67+ T cells in P1–P3 was compared between treated groups. Colors correspond to the P1–P3 populations (right). B–E, Data represent the means ± SEM of four or five mice. Data are representative of two independent experiments. *, P < 0.05; **, P < 0.01, one-way ANOVA analysis. Partha S. Chowdhury et al. Cancer Immunol Res 2018;6:1375-1387 ©2018 by American Association for Cancer Research